These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2214189)

  • 1. [VAD chemotherapy of multiple myeloma].
    Amano M; Itoh K; Togawa A
    Rinsho Ketsueki; 1990 Jul; 31(7):917-21. PubMed ID: 2214189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
    Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [VAD regimen for multiple myeloma--the effectiveness as first line therapy].
    Fujii Y; Nisimura Y; Tanizawa Y; Azuno Y; Yaga K; Hirosige Y; Kaku K; Kaneko T; Matumoto N
    Rinsho Ketsueki; 1991 Mar; 32(3):280-2. PubMed ID: 2041172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD).
    Adam Z; Elbl L; Vorlicek J; Hájek R; Hájek D; Hejlová N; Králová E; Novotná H
    Acta Med Austriaca; 1994; 21(4):111-5. PubMed ID: 7871966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.
    Segeren CM; Sonneveld P; van der Holt B; Baars JW; Biesma DH; Cornellissen JJ; Croockewit AJ; Dekker AW; Fibbe WE; Löwenberg B; van Marwijk Kooy M; van Oers MH; Richel DJ; Schouten HC; Vellenga E; Verhoef GE; Wijermans PW; Wittebol S; Lokhorst HM
    Br J Haematol; 1999 Apr; 105(1):127-30. PubMed ID: 10233375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative evaluation of treatment results in advanced multiple myeloma with the help of polychemotherapy with vincristine, doxorubicin, dexamethasone (VAD) or only with dexamethasone].
    Hansz J; Włodarczyk M; Psuja P
    Acta Haematol Pol; 1992; 23(4):277-84. PubMed ID: 1293910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The efficacy of VAD chemotherapy for refractory lymphoid malignancies].
    Gotoh H; Oku N; Inaba T; Murakami S; Oku N; Takeda N; Itoh K; Fujita N; Ura Y; Nakanishi S
    Rinsho Ketsueki; 1991 Aug; 32(8):822-30. PubMed ID: 1942521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.
    Cook G; Clark RE; Morris TC; Robertson M; Lucie NP; Anderson S; Paul J; Franklin IM
    Br J Haematol; 2004 Sep; 126(6):792-8. PubMed ID: 15352982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
    Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
    Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].
    Adam Z; Matýková M; Krejcí M; Pour L; Kissová J; Slechtová M; Chlupová G; Stavarová Y; Simonides J; Penka M; Mayer J; Hájek R
    Vnitr Lek; 2010 Jan; 56(1):67-78. PubMed ID: 20184115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ambulatory therapy of multiple myeloma with vincristine, adriamycin and dexamethasone].
    Egerer G; Hegenbart U; Salwender H; Hahn U; Haas R; Goldschmidt H; Hunstein W
    Dtsch Med Wochenschr; 1997 Apr; 122(17):531-5. PubMed ID: 9190299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Progress in the treatment of multiple myeloma].
    Wada M; Mizoguchi H
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1079-88. PubMed ID: 9239160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
    Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C
    J BUON; 2007; 12(1):41-4. PubMed ID: 17436400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of cyclophosphamide and dexamethasone in advanced refractory multiple myeloma patients.
    Celesti L; Clavio M; Poggi A; Casciaro S; Vallebella E; Gobbi M
    Haematologica; 1997; 82(3):351-3. PubMed ID: 9234590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of resistant multiple myeloma with vincristine, adriamycin and dexamethasone (VAD).
    Maniatis A; Stamatellou M; Papanastasiou K
    Chemioterapia; 1987 Jun; 6(2 Suppl):727-8. PubMed ID: 3509532
    [No Abstract]   [Full Text] [Related]  

  • 18. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
    Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
    Ai Zheng; 2007 Dec; 26(12):1369-72. PubMed ID: 18076804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
    Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW
    Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lower cardiotoxicity of adriamycin during continuous administration in patients with refractory multiple myeloma treated with cyclophosphamide, vincristine, adriamycin and dexamethasone (C-VAD)].
    Adam Z; Elbl L; Vorlícek J; Hájek R; Tomíska M; Hejlová N; Králová E; Novotná H
    Vnitr Lek; 1994 Aug; 40(8):506-12. PubMed ID: 7941437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.